X

Indication

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia... read more

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis. read more

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis.

Limitations of Use

  • Aranesp® has not been shown to improve quality of life, fatigue, or patient well-being.
  • Aranesp® is not indicated for use as a substitute for red blood cell transfusions in patients who require immediate correction of anemia.
› Email› Print

Annual transfusions have increased since 20101

In 2013, the annual percent of patients with at least 1 RBC transfusion had increased to 22%1

Prevalent Medicare Patient on Dialysis, 2009-2013

The trend of increased transfusion rates was similar for all patient characteristics, including age, dialysis vintage, gender, and race1,*


*This is a retrospective study to assess transfusion events in Medicare patients on hemodialysis or peritoneal dialysis at the beginning of each year with follow-up through December 31, death, transplantation, or loss to follow-up during calendar years 2009-2013. Descriptive analyses relating to study outcomes were conducted in both the overall population as well as stratified by modality, dialysis duration, age, sex, and hemoglobin level. Patient population in each calendar year: 2009 N = 252,627; 2010 N = 263,801; 2011 N = 273,676; 2012 N = 282,410; 2013 N = 281,996.

Based on the changing trend, CMS stated they will continue to monitor the rate of transfusions2

Indication

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis.

    Limitations of Use:

  • Aranesp® has not been shown to improve quality of life, fatigue, or patient well-being.
  • Aranesp® is not indicated for use as a substitute for red blood cell transfusions in patients who require immediate correction of anemia.

Scroll down for additional
Important Safety Information.

Abbreviations and References:
CMS = Centers for Medicare & Medicaid Services; RBC = red blood cell.
References: 1. Data on file. Amgen; [Chronic Disease Research Group: Annual Transfusion Proportion and Rate in Patients Receiving Hemodialysis and Peritoneal Dialysis. August 2015]. 2. Centers for Medicare & Medicaid Services. Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Bad Debt Reductions for All Medicare Providers. [CMS- 1352-F]. Fed Regist. 2012;77:67450-67531. 42 CFR Parts 413 and 417.